News Conference News ACC 2017 MitraClip Commercial Experience at 1 Year Sheds Light on Progress and Lingering Concerns L.A. McKeown March 27, 2017
News Conference News ACC 2017 My Takeaways From ACC 2017: Even With a Sea Change, the Tide Takes Its Time Shelley Wood March 23, 2017
News Conference News ACC 2017 Prioritizing Impella Support May Boost Cardiogenic Shock Survival, Pilot Study Suggests Todd Neale March 22, 2017
News Conference News ACC 2017 CMR Perfusion Imaging Holds Its Own Against Invasive Approach to Managing Stable Angina Todd Neale March 22, 2017
News Conference News ACC 2017 High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI Michael O'Riordan March 21, 2017
News Conference News ACC 2017 Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS Michael O'Riordan March 19, 2017
News Conference News ACC 2017 Cerebral Embolic Protection During Surgical AVR Fails to Show a Benefit Todd Neale March 19, 2017
News Conference News ACC 2017 DECISION-CTO: PCI Stumbles for Stable CAD Patients With Chronic Total Occlusions Yael L. Maxwell March 19, 2017
Presentation ACC 2017 Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results Presenter: Stephen G. Ellis March 19, 2017
News Conference News ACC 2017 ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience Michael O'Riordan March 18, 2017
News Conference News ACC 2017 FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS Michael O'Riordan March 18, 2017
News Conference News ACC 2017 iFR Matches FFR for Clinical Outcomes in Patients With Intermediate Lesions Caitlin E. Cox March 18, 2017
News Conference News ACC 2017 Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe Todd Neale March 18, 2017
News Conference News ACC 2017 SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients Todd Neale March 17, 2017
News Conference News ACC 2017 FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo Michael O'Riordan March 17, 2017
News Conference News ACC 2017 ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More Shelley Wood March 10, 2017
News Conference News ACC 2017 More Certainty With Ceramides? New Blood Test May Help ID CAD Patients Early in Disease Yael L. Maxwell March 09, 2017
News Conference News ACC 2016 DANAMI3: Deferred Stenting, Ischemic Postconditioning No Help in STEMI Todd Neale April 04, 2016
News Conference News ACC 2015 SCOT-HEART Provides Support for Coronary CTA in Angina Management L.A. McKeown March 15, 2015